Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US scientists target mosquitoes with nanoparticles

Researchers at the US University of Kansas have been awarded a US patent (8,841,272) for controlling mosquitoes and other insects with double-stranded RNA (dsRNA)-based nanoparticles. Ingested nanoparticles release dsRNA that destroys specific messenger RNA (mRNA). In studies on mosquito larvae, the scientists designed dsRNA to target mRNA encoding enzymes involved in the production of chitin. Developing mosquitoes produced less chitin and were more prone to insecticides. The technique is applicable to other insect pests. "You can design species-specific dsRNA for the same or different genes for other insect pests," says professor of entomology Kun Yan Zhu. "When you make baits containing gene-specific nanoparticles, you may be able to kill the insects through the RNAi pathway. We see this as having really broad applications for insect pest management." The patent is available to license through the Kansas State University Institute for Commercialization.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG002797

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel